A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn’s disease

References

• Billiet T, Rutgeerts P, Ferrante M, et al. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opin Biol Ther. 2014;14:75–101.
   PubMed Web of Science ®Google Scholar
• Ferrante M, Vermeire S, Rutgeerts PJ. Drug safety evaluation of certolizumab pegol. Expert Opin Drug Saf. 2014;13:255–266.
   PubMed Web of Science ®Google Scholar
• Pagnini C, Arseneau KO, Cominelli F. Safety considerations when using anti-TNFα therapy to treat Crohn’s disease. Expert Opin Drug Saf. 2015;14:31–44.
   PubMed Web of Science ®Google Scholar
• Khanna R, Feagan BG. Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events. Expert Opin Drug Saf. 2015;14:987–997.
   PubMed Web of Science ®Google Scholar
• Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699–1708.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Sands BE, Blank MA, Patel K, et al.. Long-term treatment of rectovaginal fistulas in Crohn’s disease: response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol. 2004;2:912–920.
   PubMed Web of Science ®Google Scholar
• Lémann M, Mary J-Y, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006;130:1054–1061.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al.. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al.. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 2006;130:323–333.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al.. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P, et al.. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–1239.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R, et al.. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 2007;146:829–838.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Van Assche G, Sandborn WJ, et al.. Colombel JF et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012;142(1102–1111):e2.
   Google Scholar
• Watanabe M, Hibi T, Lomax KG, et al. Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn’s disease. J Crohns Colitis. 2012;6:160–173.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Rutgeerts P, Fedorak RN, et al. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn’s disease. Gastroenterology. 2005;129:807–818.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S, et al.. Certolizumab pegol for the treatment of Crohn’s disease. N Engl J Med. 2007;357:228–238.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al.. Maintenance therapy with certolizumab pegol for Crohn’s disease. N Engl J Med. 2007;357:239–250.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Schreiber S, Feagan BG, et al.. Certolizumab pegol for active Crohn’s disease: a placebo-controlled, randomized trial. Clin Gastroenterol Hepatol. 2011;9:670–678.
   PubMed Web of Science ®Google Scholar
• Fidder H, Schnitzler F, Ferrante M, et al.. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut. 2009;58:501–508.
   PubMed Web of Science ®Google Scholar
• Eshuis EJ, Peters CP, Van Bodegraven AA, et al. Ten years of infliximab for Crohn’s disease: outcome in 469 patients from 2 tertiary referral centers. Inflamm Bowel Dis. 2013;19:1622–1630.
   PubMed Web of Science ®Google Scholar
• Seminerio JL, Jr LEV, Colombel JF, et al. Infliximab for Crohn’s disease: the first 500 patients followed up through 2009. Dig Dis Sci. 2013;58:797–806.
   PubMed Web of Science ®Google Scholar
• Stephens MC, Shepanski MA, Mamula P, et al. Safety and steroid-sparing experience using infliximab for Crohn’s disease at a pediatric inflammatory bowel disease center. Am J Gastroenterol. 2003;98:104–111.
   PubMed Web of Science ®Google Scholar
• Karmiris K, Paintaud G, Noman M, et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease. Gastroenterology. 2009;137:1628–1640.
   PubMed Web of Science ®Google Scholar
• Swoger JM, Loftus EV Jr, Tremaine WJ, et al. Adalimumab for Crohn’s disease in clinical practice at Mayo clinic: the first 118 patients. Inflamm Bowel Dis. 2010;16:1912–1921.
   PubMed Web of Science ®Google Scholar
• Rosh JR, Lerer T, Markowitz J, et al. Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric Crohn’s disease. Am J Gastroenterol. 2009;104:3042–3049.
   PubMed Web of Science ®Google Scholar
• Lees CW, Ali AI, Thompson AI, et al. The safety profile of anti-tumour necrosis factor therapy in inflammatory bowel disease in clinical practice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ther. 2009;29:286–297.
   PubMed Web of Science ®Google Scholar
• Riis A, Martinsen TC, Waldum HL, et al. Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn’s disease. Scand J Gastroenterol. 2012;47:649–657.
   PubMed Web of Science ®Google Scholar
• Assa A, Hartman C, Weiss B, et al. Long-term outcome of tumor necrosis factor alpha antagonist’s treatment in pediatric Crohn’s disease. J Crohns Colitis. 2013;7:369–376.
   PubMed Web of Science ®Google Scholar
• Nuti F, Viola F, Civitelli F, et al. Biological therapy in a pediatric Crohn disease population at a referral center. J Pediatr Gastroenterol Nutr. 2014;58:582–587.
   PubMed Web of Science ®Google Scholar
• Moon W, Pestana L, Becker B, et al. Efficacy and safety of certolizumab pegol for Crohn’s disease in clinical practice. Aliment Pharmacol Ther. 2015;42:428–440.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Lee SD, Randall C, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn’s disease: 7-year results from the PRECiSE 3 study. Aliment Pharmacol Ther. 2014;40:903–916.
   PubMed Web of Science ®Google Scholar
• Jauregui-Amezaga A, Turon F, Ordas I, et al. Risk of developing tuberculosis under anti-TNF treatment despite latent infection screening. J Crohns Colitis. 2013;7:208–212.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Hendler SA, Cohen BL, Colombel JF, et al. High-dose infliximab therapy in Crohn’s disease: clinical experience, safety, and efficacy. J Crohns Colitis. 2015;9:266–275.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al.. Serious infection and mortality in patients with Crohn’s disease: more than 5 years of follow-up in the TREAT™ registry.. Am J Gastroenterol. 2012;107:1409–1422.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Satsangi J, et al.. PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 6. J Crohns Colitis. 2015;9(suppl 1):S42–S44.
   Google Scholar
• Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104:2524–2533.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al.. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051–1063.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Panaccione R, et al.. Adalimumab safety in global clinical trials of patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1308–1319.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, De Suray N, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo controlled trials. Clin Gastroenterol Hepatol. 2008;6:644–653.
   PubMed Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
   PubMed Web of Science ®Google Scholar
• Biancone L, Petruzziello C, Orlando A, et al. Cancer in Crohn’s disease patients treated with infliximab: a long-term multicenter matched pair study. Inflamm Bowel Dis. 2011;17:758–766.
   PubMed Web of Science ®Google Scholar
• Long MD, Martin CF, Pipkin CA, et al. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390–399.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al.. Drug therapies and the risk of malignancy in Crohn’s disease: results from the TREAT™ Registry. Am J Gastroenterol. 2014;109:212–223.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Reinisch W, Colombel J-F, et al. Five-year safety results from the ENCORE registry: Malignancies in patients with Crohn’s disease treated with infliximab, standard therapy, or switched from standard therapy to infliximab. J Crohns Colitis. 2014;8(S1):S63.
   Google Scholar
• Long MD, Herfarth HH, Pipkin CA, et al. Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2010;8:268–274.
   PubMed Web of Science ®Google Scholar
• Williams CJ, Peyrin-Biroulet L, Ford AC. Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39:447–458.
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–524.
   PubMed Web of Science ®Google Scholar
• Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146–2153.
   PubMed Web of Science ®Google Scholar
• Deepak P, Sifuentes H, Sherid M, et al.. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874–881.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al.. A systematic review of factors that contribute to hepatosplenic T-Cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:36–41.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Vermeire S. Paradoxical inflammation induced by anti-TNF agents in patients with IBD. Nat Rev Gastroenterol Hepatol. 2012;9:496–503.
   PubMed Web of Science ®Google Scholar
• Coutzac C, Chapuis J, Poullenot F, et al.. Association between infliximab trough levels and the occurrence of paradoxical manifestations in patients with inflammatory bowel disease: a case-control study. J Crohns Colitis. 2015;9:982–987.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Buche S, Peyrin-Biroulet L, et al. Severe skin lesions cause patients with inflammatory bowel disease to discontinue anti-tumor necrosis factor therapy. Clin Gastroenterol Hepatol. 2010;8:1048–1055.
   PubMed Web of Science ®Google Scholar
• Cullen G, Kroshinsky D, Cheifetz AS, et al. Psoriasis associated with anti-tumour necrosis factor therapy in inflammatory bowel disease: a new series and a review of 120 cases from the literature. Aliment Pharmacol Ther. 2011;34:1318–1327.
   PubMed Web of Science ®Google Scholar
• George LA, Gadani A, Cross RK, et al.. Psoriasiform skin lesions are caused by anti-TNF agents used for the treatment of inflammatory bowel disease. Dig Dis Sci. 2015;60:3424–3430.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Guidi L, Ferraro PM, et al.. Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study. Aliment Pharmacol Ther. 2015;42:880–888.
   PubMed Web of Science ®Google Scholar
• Fréling E, Baumann C, Cuny JF, et al.. Cumulative incidence of, risk factors for, and outcome of dermatological complications of anti-TNF therapy in inflammatory bowel disease: a 14-year experience. Am J Gastroenterol. 2015;110:1186–1196.
   PubMed Web of Science ®Google Scholar
• Wang F, Lin X, Zhao Q, et al.. Adverse symptoms with anti-TNF-alpha therapy in inflammatory bowel disease: systematic review and duration-response meta-analysis. Eur J Clin Pharmacol. 2015;71:911–919.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617–1625.
   PubMed Web of Science ®Google Scholar
• Singh S, Nagpal SJ, Murad MH, et al. Inflammatory bowel disease is associated with an increased risk of melanoma: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:210–218.
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al., Cesame Study Group. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621–1628.
   PubMed Web of Science ®Google Scholar
• Deepak P, Stobaugh DJ, Ehrenpreis ED. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System. J Gastrointestin Liver Dis. 2013;22:269–276.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Siegel CA, Peyrin-Biroulet L. Anti-tumor necrosis factor-α monotherapy versus combination therapy with an immunomodulator in IBD. Gastroenterol Clin North Am. 2014;43:441–456.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Thompson KD, Blunt HB, et al. Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review. Clin Gastroenterol Hepatol. 2014;12:1443–1451.
   PubMed Web of Science ®Google Scholar
• Jones JL, Kaplan GG, Peyrin-Biroulet L, et al.. Effects of concomitant immunomodulator therapy on efficacy and safety of anti-tumor necrosis factor therapy for Crohn’s disease: A meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2015;13:2233-2240.e2.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque BG, et al.. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015;386:1825–1834.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials.. Aliment Pharmacol Ther. 2009;30:210–226.
   PubMed Web of Science ®Google Scholar
• Nyboe Andersen N, Pasternak B, Basit S, et al. Association between tumor necrosis factor-α antagonists and risk of cancer in patients with inflammatory bowel disease.. Jama. 2014;311:2406–2413.
   PubMed Web of Science ®Google Scholar
• Wang Z, Wang J, Fu L, et al. Effectiveness and risk associated with infliximab alone and in combination with immunosuppressors for Crohn’s disease: a systematic review and meta-analysis. Int J Clin Exp Med. 2015;8:4846–4854.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Haynes K, Delzell E, et al. Effectiveness and safety of immunomodulators with anti-tumor necrosis factor therapy in Crohn’s Disease. Clin Gastroenterol Hepatol. 2015;13:1293–1301.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014;146:941–949.
   PubMed Web of Science ®Google Scholar
• Schnitzler F, Fidder H, Ferrante M, et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis. 2011;17:1846–1854.
   PubMed Web of Science ®Google Scholar
• Seirafi M, De Vroey B, Amiot A, et al. Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:363–373.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Martin CF, Sandler RS, et al.. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142(Suppl 5):S149.
   Google Scholar
• Deepak P, Stobaugh DJ. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease. Aliment Pharmacol Ther. 2014;40:1035–1043.
   PubMed Web of Science ®Google Scholar
• Bröms G, Granath F, Ekbom A, et al.. Low risk of birth defects for infants whose mothers are treated with anti-tumor necrosis factor agents during pregnancy. Clin Gastroenterol Hepatol. 2016;14:234–241.
   Web of Science ®Google Scholar
• Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: a systematic literature review.. World J Gastroenterol. 2013;19:2591–2602.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Abdolghaffari AH, Nikfar S, et al. Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis. Hum Exp Toxicol. 2015;34:445–459.
   PubMed Web of Science ®Google Scholar
• Narula N, Al-Dabbagh R, Dhillon A, et al. Anti-TNFα therapies are safe during pregnancy in women with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2014;20:1862–1869.
   PubMed Web of Science ®Google Scholar
• Van Der Woude CJ, Ardizzone S, Bengtson MB, et al.. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107–124.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286–292.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Gisbert JP. How safe is infliximab therapy during pregnancy and lactation in inflammatory bowel disease?. Expert Opin Drug Saf. 2014;13:1749–1762.
   PubMed Web of Science ®Google Scholar
• De Greef E, Hoffman I, D’Haens G, et al. Safety and cost of infliximab for the treatment of Belgian pediatric patients with Crohn’s disease. Acta Gastroenterol Belg. 2012;75:425–431.
   PubMed Web of Science ®Google Scholar
• Cameron FL, Wilson ML, Basheer N, et al. Anti-TNF therapy for paediatric IBD: the Scottish national experience. Arch Dis Child. 2015;100:399–405.
   PubMed Web of Science ®Google Scholar
• Veereman-Wauters G, De Ridder L, Veres G, et al;; ESPGHAN IBD Porto Group. Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary. J Pediatr Gastroenterol Nutr. 2012;54:830–837.
   PubMed Web of Science ®Google Scholar
• Lobatón T, Ferrante M, Rutgeerts P, et al. Efficacy and safety of anti-TNF therapy in elderly patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2015;42:441–451.
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9:30–35.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al.. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443–468.
   PubMed Web of Science ®Google Scholar
• Ferkolj I. How to improve the safety of biologic therapy in Crohn’s disease. J Physiol Pharmacol. 2009;60(Suppl 7):67–70.
   PubMed Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al.. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015 Aug 20;9:945–965.
   PubMed Web of Science ®Google Scholar
• Ha C, Ullman TA, Siegel CA, et al.. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10:1002–1007.
   PubMed Web of Science ®Google Scholar
• Brandse JF, Vos LM, Jansen J, et al. Serum concentration of anti-TNF antibodies, adverse effects and quality of life in patients with inflammatory bowel disease in remission on maintenance treatment. J Crohns Colitis. 2015;9:973–981.
   PubMed Web of Science ®Google Scholar
• Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery.. Ann Surg. 2015;261:487–496.
   PubMed Web of Science ®Google Scholar
• Cleynen I, Moerkercke WV, Billiet T, et al.. Characteristics of skin lesions associated with anti-tumor necrosis factor therapy in patients with inflammatory bowel disease: a cohort study. Ann Intern Med. 2016;164:10–22.
   PubMed Web of Science ®Google Scholar
• Huang V, Dhami N, Fedorak D, et al. A study investigating the association of dermatological and infusion reactions to infliximab and infliximab trough levels. Can J Gastroenterol Hepatol. 2015;29:35–40.
   PubMed Web of Science ®Google Scholar
• Williet N, Paul S, Peyrin-Biroulet L, et al.. Pharmacokinetics of infliximab and reduction of treatment for inflammatory bowel diseases. Dig Dis Sci. 2015 Dec 15. PMID:26669880. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Papamichael K, Van Stappen T, Jairath V, et al. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases. Aliment Pharmacol Ther. 2015;42:1158–1169.
   PubMed Web of Science ®Google Scholar